xl418
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2007 (NCT00460278)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
Serine/threonine-protein kinase AKT inhibitor
- Ribosomal protein S6 kinase (P70S6K)INHIBITOR
Ribosomal protein S6 kinase (P70S6K) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1c(NCCN2CCCC2)cc(C(=O)CCC(F)(F)F)cc1N1CCN(c2ncnc3[nH]nc(Br)c23)CC1- Mol. weight
- 609.5 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3544935 ↗
- ChEMBLCHEMBL2016893 ↗
Also known as
- xl418
- xl418
- xl-418
- xl-418
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00460278 | Phase 1 | Apr 1, 2007 | Exelixis |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exelixis | For profit | 1 | 1 | 1 | 2007 |
1 organizations
Page 1 / 1